Session Details

S046 Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfall for the General Dermatologist

Mon, Mar 22, 9:00 AM - 12:00 PM
3 CME Available Symposium

DESCRIPTION

A case-based approach will be utilized to describe practical clinical scenarios that will enable the resident or general dermatologist to appropriately diagnose and manage patients with cutaneous lupus erythematosus and dermatomyositis. The importance of a thorough and intentional clinical examination will be emphasized to help participants build confidence in accurately diagnosing these relatively rare and often challenging to diagnose conditions. Participants will learn to develop treatment algorithms incorporating typical modalities such as sun protection, topical therapies, and antimalarials, as well as other systemic medications. The evidence for the effectiveness of these agents and their safe use in adults and children will be reviewed. Participants will be able to identify when to initiate systemic immunosuppressive therapy and/or refer to other specialists. Participants will also develop a strategy to appropriately work-up these potentially systemic conditions. Complex cases will also be reviewed.

LEARNING OBJECTIVES

1.

Utilize clinical examination to aid in accurate diagnosis of patients with cutaneous lupus erythematosus and dermatomyositis.

2.

Develop a treatment strategy for cutaneous lupus and cutaneous dermatomyositis that incorporates modalities including sun protection, topical therapies, and systemic medications.

3.

Describe associated systemic complications of cutaneous lupus and dermatomyositis and screen appropriately for them.

DIRECTOR

Alisa Femia, MD, FAAD

Alisa Femia, MD, FAAD

NYU School of Medicine

SPEAKERS

John R. Edminister, MD, FAAD

John R. Edminister, MD, FAAD

Wake Forest School of Medicine

Jeffrey R. Gehlhausen, MD, PhD, FAAD

Jeffrey R. Gehlhausen, MD, PhD, FAAD

Yale Department of Dermatology and Dermatopathology

Allen Wayne Ho, MD, PhD, FAAD

Allen Wayne Ho, MD, PhD, FAAD

Daniel Mazori, MD, FAAD

Daniel Mazori, MD, FAAD

Christopher T. Richardson, PhD, MD, FAAD

Christopher T. Richardson, PhD, MD, FAAD

University of Rochester Medicine

David A. Wetter, MD, FAAD

David A. Wetter, MD, FAAD

Jennifer Yeh, MD, PhD, FAAD

Jennifer Yeh, MD, PhD, FAAD

Stanford University School of Medicine

DISCLOSURES

John R. Edminister, MD, FAAD

Hyloris Pharmaceuticals – Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Wake Forest University Health Sciences – Employee (w-2 relationship)(Patent royalties or other compensation for Intellectual Property Rights); WebMD – Speaker(Fees);

Alisa Femia, MD, FAAD

Astra Zeneca – Consultant (1099 relationship)(Honoraria); Biogen – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); EMD Serono – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Veradermics – Consultant (1099 relationship)(Honoraria);

Jeffrey R. Gehlhausen, MD, PhD, FAAD

AstraZeneca – Investigator(Grants/Research Funding); Priovant – Consultant (1099 relationship)(Fees);

Allen Wayne Ho, MD, PhD, FAAD

No financial relationships exist with ineligible companies.

Daniel Mazori, MD, FAAD

Veradermics – Advisory Board(Fees);

Christopher T. Richardson, PhD, MD, FAAD

AstraZeneca – Investigator(Grants/Research Funding); Biogen – Advisory Board(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Priovant – Investigator(Grants/Research Funding); Priovant Therapeutics – Advisory Board(Fees);

David A. Wetter, MD, FAAD

No financial relationships exist with ineligible companies.

Jennifer Yeh, MD, PhD, FAAD

No financial relationships exist with ineligible companies.